This is a working overview of Fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
== Causes == Acanthosis nigricans arises from several distinct mechanisms. It most commonly reflects insulin resistance and is frequently associated with type 2 diabetes, obesity and endocrine disorders such as hypothyroidism, acromegaly, polyendocrine metabolic ovarian syndrome, and Cushing's disease. It may also be inherited, medication-related or associated with internal malignancy. Review articles describe acanthosis nigricans primarily as a marker of systemic metabolic dysfunction rather than a primary skin disease.
By doing so, individuals with masculinized brains are better able to survive and copulate with as many mates as possible. The masculinization of the brain is mediated both by testosterone levels at the adult stage and by testosterone exposure in the womb. Higher pre-natal testosterone indicated by a low digit ratio as well as adult testosterone levels increased risk of fouls or aggression among male players in a soccer game. Studies have found higher pre-natal testosterone or lower digit ratio to be correlated with higher aggression. The rise in testosterone during competition predicted aggression in males, but not in females. In one experiment, subjects who interacted with handguns showed higher testosterone levels and aggression than those who interacted with toys. One study proposed that natural selection may have caused men to be more sensitive to situations in which their status is challenged, and that testosterone is the key factor that causes these situations to spark into aggression. Structural brain characteristics associated with testosterone levels have also been found to predict individuals' levels of aggression. The Annals of the New York Academy of Sciences has found that the use of anabolic steroids (which increases testosterone) among teenagers is correlated with increased likelihood of using violence. One study found that administering testosterone increased verbal aggression in some participants. A few studies indicate that the testosterone derivative estradiol might play an important role in male aggression.
== Medical uses == Diclofenac is used to treat pain related to arthritis, dysmenorrhea, rheumatic diseases and other inflammatory disorders, kidney stones and gallstones. An additional indication is the treatment of acute migraines. Diclofenac is used to treat mild to moderate postoperative or post-traumatic pain, in particular when inflammation is also present. Diclofenac ophthalmic is indicated for the treatment of postoperative inflammation in people who have undergone cataract extraction and for the temporary relief of pain and photophobia in people undergoing corneal refractive surgery. Diclofenac may also help with actinic keratosis and with acute pain caused by minor strains, sprains and contusions. In many countries, eye drops are sold to treat acute and chronic nonbacterial inflammation of the anterior part of the eyes (such as postoperative states). The eye drops have also been used to manage pain for traumatic corneal abrasion. Diclofenac is often used to treat chronic pain associated with cancer, especially if inflammation is present.
Mepsy (formerly Policy Analysis Modeling System (PAMS)) Based on the Policy Analysis Modeling System created by CLASP and the Lawrence Berkeley National Laboratory (LBNL), Mepsy is as an easy-to-use software tool to help local policymakers assess the benefit of standards and labeling programs, and to identify the most attractive targets for appliances and efficiency levels. CLASP Policy Resource Center (CPRC) (formerly Global S&L Database) The CLASP Policy Resource Center is an online resource that allows policy makers and S&L practitioners to compare appliance, lighting, and equipment efficiency policies and regulations across countries and by product; to explore specific information about those policies; and to view and understand the legislative framework and history of S&L by country and economic region. VeraSol (formerly Lighting Global Quality Assurance) VeraSol evolved from Lighting Global Quality Assurance, a quality assurance initiative for off-grid solar products supported by the World Bank. Products in the database display technical information that can be compared across appliance categories and have been undergone testing in certified laboratories.
=== Solvent interface trapping method (SITM) === As reported by a group led by D. H. Adamson, graphene can be produced from natural graphite while preserving the integrity of the sheets using the solvent interface trapping method (SITM). SITM uses a high-energy interface, such as oil and water, to exfoliate graphite to graphene. Stacked graphite delaminates, or spreads, at the oil/water interface to produce few-layer graphene in a thermodynamically favorable process in much the same way as small molecule surfactants spread to minimize the interfacial energy. In this way, graphene behaves like a 2D surfactant. SITM has been reported for a variety of applications such conductive polymer-graphene foams, conductive polymer-graphene microspheres, conductive thin films and conductive inks.
Sources: en.wikipedia.org
Macroamylasemia is the presence of macroamylase in the blood. Macroamylase is a complex of the enzyme amylase bound to other proteins forming a larger molecule. Macroamylase is typically composed of immunoglobulin A (IgA, 70%) and less often of immunoglobulin G (IgG, 30%). The association of amylase with some drugs has also been reported.
Carbon fibers are filaments of carbon that can be used to make very strong yarns and textiles. Carbon fiber items are often produced by spinning and weaving the desired item from fibers of a suitable polymer, and then pyrolyzing the material at a high temperature (from 1,500–3,000 °C or 2,730–5,430 °F). The first carbon fibers were made from rayon, but polyacrylonitrile has become the most common starting material. For their first workable electric lamps, Joseph Wilson Swan and Thomas Edison used carbon filaments made by pyrolysis of cotton yarns and bamboo splinters, respectively. Pyrolysis is the reaction used to coat a preformed substrate with a layer of pyrolytic carbon. This is typically done in a fluidized bed reactor heated to 1,000–2,000 °C or 1,830–3,630 °F. Pyrolytic carbon coatings are used in many applications, including artificial heart valves.
== Legacy == His career in the industry is acknowledged through the "Frank Vale Award" which is presented annually at the Refrigerated Warehouse and Transport Association of Australia (RWTA) Conference and Exhibition to an outstanding young achiever.
Smithfield hams are a specific variety of country hams which are cured by the long-cure, dry salt method and aged for a minimum period of six months within the limits of the town of Smithfield, Virginia, United States Soppressata – an Italian dry salami. Two principal types are made, a cured dry sausage typical of Basilicata, Apulia and Calabria, and a very different uncured salami, native to Tuscany and Liguria. Speck – in parts of the English-speaking culinary world, the term "Speck" refers to Italian Speck, a type of prosciutto. Speck is also an English word meaning "fat" or "blubber", attested since the early 17th century. Suho meso – a smoked beef food preparation eaten in Bosnian cuisine and Serbian cuisine. Sukuti – the Nepali word for dry meat (jerky). Sukuti is either consumed directly or charbroiled and spiced as an appetizer or snack or mixed with other ingredients and served as side dish.
Informal prescreening: In some cases, countries can introduce controls that function as border controls but are not border controls legally, and do not need to be performed by government agencies. Normally, they are performed and organised by private companies, under a law that requires them to check whether passengers are allowed to travel to a specific country. Such controls can take effect in one country based on the laws of another country, without any formalised border-control prescreening agreement in force. Even if they are not, border controls function as such. The most prominent example is airlines that check passports and visas before passengers are allowed to board. Also, for some passenger boats, such checks are performed before boarding.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.